Samaritan Pharmaceuticals - Transforming Today's Science into Tomorrow's Cures

Samaritan's Chief Drug Development Officer to Present Lead Alzheimer's Drug At 12th IBC World Congress
Thursday August 2, 10:05 am ET

Return to Homepage | See All News

Focus Area: New and Emerging Therapeutic Targets for CNS
Topic: SP-233: A New and Novel Therapy With Protective Properties Against the Neurotoxic Effects of Beta-Amyloid Peptide

Samaritan Pharmaceuticals, Inc. (OTC BB:SPHC.OB - website), a developer of innovative drugs, announced today that Dr. Thomas Lang, its Chief Drug Development Officer, will speak at the 12th annual International Business Communication (IBC) World Congress. The conference is focusing on Drug Discovery & Development of Innovative Therapeutics, and Dr. Lang is presenting Samaritan's lead Alzheimer's drug SP-233 as a new and novel Alzheimer's therapy on Aug. 7, 2007 at 9:30 EDT.

Dr. Lang, who has over twenty-five years of experience in the pharmaceutical industry, will highlight that Caprospinol/SP-233 has promising ``proof of concept'' data demonstrating that the clearing of beta-amyloid plaque from the brain leads to a restoration of memory in animals.

IBC's World Congress on Drug Discovery & Development of Innovative Therapeutics is featuring Dr. Craig Mello, 2006 Nobel Prize winner and numerous other industry thought leaders, and is at the World Trade Center in Boston, MA, August 6-9, 2007.

Samaritan Pharmaceuticals: ``Transforming Today's Science Into Tomorrow's Cures...''
Samaritan Pharmaceuticals is a life science company focused on commercializing innovative drugs to relieve the suffering of patients with Alzheimer's, cancer, heart disease, and infectious disease. Samaritan's business strategy is to partner its later stage drugs after Phase II (proof of concept) human studies and has executed its first partnership for its PII, HIV drug SP-01A, with Pharmaplaz, Ireland. The FDA has authorized an investigational new drug (IND) # and a Phase I for its Alzheimer's drug Caprospinol and Samaritan has several other drugs it is advancing to enter (IND) status. In addition, Samaritan's sales arm has acquired the marketing and sales rights to sell ten revenue-generating products in Greece and various Eastern European countries.

Website: http://www.samaritanpharma.com. Please register so we can notify you of upcoming conference calls, news and events.

Disclaimer:
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings, and Website. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science, and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 13, 2007. The company undertakes no duty to update forward-looking statements.

Contact:
The Investor Relations Group
Investor Relations:
Adam Holdsworth
Erica Ruderman
Rachel Colgate
212-825-3210

Samaritan Pharmaceuticals, Inc.
Kristi Eads
702-735-7001